" /> Alnuctamab - CISMeF





Preferred Label : Alnuctamab;

NCIt synonyms : BCMA/CD3-directed Bispecific T-cell Engager Antibody CC-93269; Anti-BCMA/CD3 Bispecific Antibody CC-93269; BCMA x CD3 T Cell Engaging Antibody CC-93269; BCMA x CD3 T-cell Engaging Antibody CC-93269; BCMAxCD3 TCB CC-93269; BCMAxCD3 BiTE Antibody CC-93269; Bi-specific Antibody CC-93269; ALNUC; BCMA/CD3 T-cell Bi-specific Antibody CC-93269;

NCIt definition : A bispecific T-cell engager (BiTE) antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, alnuctamab binds bivalently to BCMA expressed on tumor cells and monovalently to CD3 expressed on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.;

UNII : 7OSV6M6T4D;

CAS number : 2296827-07-9;

Molecule name : CC 93269; BMS-986349; BMS 986349; CC-93269; EM901;

NCI Metathesaurus CUI : CL1413154;

Détails


Position du mot-clé dans l'(les) arborescence(s) : arborescence

Vous pouvez consulter :


Nous contacter.
31/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.